Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia
Status:
RECRUITING
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn if drug CMG190303 to treat Type 2 Diabetes and Dyslipidemia in adults. It will also learn about the safety of CMG190303. The main questions it aims to answer are:
-Primary Objectives:
1. To compare the change in HbA1c from baseline to 24 weeks between CMG190303 and Rosuvastatin
2. To compare the change in LDL-C from baseline to 24 weeks between CMG190303 and Dapagliflozin